

1
2
3
4
5
6
7
8
9
10
11
12

MASSIVE TRANSFUSION PROTOCOL: A BOON FOR SALVAGING PATIENTS OF MASSIVE OBSTETRIC HEMORRHAGE

A PROSPECTIVE OBSERVATIONAL STUDY IN A TERTIARY CARE CENTER

ABSTRACT

BACKGROUND: Maternal mortality remains a major global health issue, with obstetric hemorrhage as the primary cause. Timely and effective blood transfusion is crucial for maintaining organ perfusion and oxygenation. This study seeks to evaluate maternal outcomes, focusing on survival rates and life-threatening complications following massive blood transfusion.

MATERIALS AND METHODS: A prospectiveobservational study was conducted between July 2022 to January 2024 in the Department of Obstetrics and Gynecology of Shree Krishna Hospital, Karamsad, Gujarat, India which is a rural tertiary care institute catering to Anand and Kheda districts of Central Gujarat. Data included in the study were age, socioeconomic status, parity, weeks of gestation, underlying comorbidities, cause of hemorrhage, mode of management, number and ratio of blood products transfused, and complications of **Massive Transfusion (MT)**.

RESULTS: The MT utilization rate of our institute was 2.74%. The mean age of the study group was 27.3yrs with 84% belonging to the rural population. Out of all 58% were antenatal cases majority being multipara- 61.7%. Post-Partum Hemorrhage (PPH) was the most common cause of massive obstetric hemorrhage i.e. 42%. At the same time, the average time for issuing the first blood product was 12 min. Most cases could be managed conservatively -31 out of 81 using oxytocics and timely blood transfusion. Amongst the operative interventions, obstetric hysterectomy was done in 23.4 % of cases. The overall ratio of **Packed Cell Volume (PCV): Fresh Frozen Plasma (FFP): Platelet Concentrate (PC): Cryoprecipitate (CP)** in the study was **1:1.02:0.8:2**. In 46% of the cases, patients did not suffer from any MT-related complications; **Transfusion Associated Circulatory Overload (TACO)** was seen in 16% and **Transfusion Related Acute Lung Injury (TRALI)** in 7.4%. The mortality rate was 5%. Blood transfusion-related complications are observed more with PC, followed by FFP and RCC.

CONCLUSIONS:PPHwas the leading cause of obstetric hemorrhage. Maternal morbidity and mortality can be significantly reduced through early referral to a tertiary care center, prompt administration of oxytocics, and the timely initiation of massive transfusion and surgical interventions for uncontrolled bleeding. Maintaining a blood product ratio of approximately 1:1.02:0.8 for packed red blood cells (PRBCs), fresh frozen plasma (FFP), and platelets helps prevent coagulopathy, ensures adequate tissue perfusion, and shields the patient from the detrimental cycle of sepsis, hypothermia, hemodilution, and shock. PRC transfusion was maximally responsible for TRALI.

13
14
15
16

Keywords: massive transfusion protocol, post-partum haemorrhage, obstetric haemorrhage, maternal morbidity, maternal mortality

17 **1. INTRODUCTION**

18 The Massive Transfusion Protocol represents a revolutionary approach to early, proactive
19 hemostatic resuscitation for patients at high risk of substantial blood loss over a short
20 timeframe. Massive transfusion is defined as administering more than 4 units of red cell
21 concentrates (RCC) within 1 hour or over 10 units within 24 hours, with massive blood loss
22 defined as exceeding 150 ml/hr or one blood volume within 24 hours^{1,2}. Severe obstetric
23 hemorrhage is a major global issue, significantly contributing to maternal morbidity and
24 mortality. Causes of obstetric hemorrhage include placenta previa, placenta accreta, atonic
25 and traumatic postpartum hemorrhage (PPH), uterine rupture, placental abruption, and
26 uterine inversion. There is a notable increase in the incidence of massive obstetric
27 hemorrhage, often associated with a higher rate of cesarean sections³.

28
29 **Haemostatic Resuscitation** is a key approach that focuses on achieving local surgical
30 haemostasis and mitigating coagulopathy by preventing hypothermia, acidosis, and ensuring
31 the timely replacement of coagulation factors such as fibrinogen. In the context of massive
32 obstetric hemorrhage (MOH), extensive bleeding leads to reduced blood flow to the uterus.
33 This diminished perfusion causes tissue hypoperfusion, which in turn increases the
34 production of thrombomodulin by vascular endothelial cells. Thrombomodulin activates
35 protein C, setting off a cascade of irreversible events that result in elevated fibrinogen
36 degradation products and impaired uterine contractions.^{4,5} These effects are common in both
37 atonic and traumatic postpartum hemorrhage (PPH), leading to rapid deterioration of the
38 patient's condition. Consequently, implementing a Massive Transfusion Protocol (MTP)
39 becomes a crucial strategy for effectively managing MOH.

40
41 **Using a fixed ratio of red cell concentrate (RCC) to fresh frozen plasma (FFP) at 1:1, and a**
42 **RCC:FFP:Platelet ratio of 1:1:1, has been shown to provide a survival advantage within the**
43 **first 6-24 hours of massive hemorrhage, where mortality is primarily associated with**
44 **hypovolemic shock and its effects⁶. Since the pathophysiology of obstetric bleeding is similar**
45 **to that of severe trauma, applying a Massive Transfusion Protocol (MTP) with FFP/RCC or**
46 **RBC ratios similar to those used in trauma care could be beneficial for managing obstetric**
47 **hemorrhage⁷. To improve non-trauma MTPs, further prospective studies are needed to**
48 **validate these ratios and to develop screening or prediction tools that can identify which**
49 **patients will benefit most from MTP activation.**

50
51 **1.1 Aims**

52 **The aim of our study was to obtain an insight regarding maternal outcome, in the form of:**
53 **life-threatening complications and subsequent survival or mortality following a massive blood**
54 **transfusion for obstetric hemorrhage.**

55 **We secondarily also aim to acquire information related to causes and management of**
56 **massive obstetric hemorrhage, optimum blood products ratio and the time interval between**
57 **requisition and receipt of the blood products.**

58
59
60 **2. MATERIALS AND METHOD**

61
62 **2.1 Studydesign**

63 This is a prospectiveobservational study conducted in the Department of Obstetrics and
64 Gynecology in Pramukh Swami Medical College, Karamsad, Gujarat, India from July 2022 to
65 January 2024.

66
67 **2.2 Study Subjects**

68 Only Obstetric patients, both antenatal and postpartum, who had undergone massive
69 obstetric hemorrhage necessitating Massive Transfusion Protocol were included in the
70 study. Patients with gynecological hemorrhage were excluded in the study.

71

72 **2.3 Setting**

73 This prospective, observational study was conducted in the Department of Obstetrics and
74 Gynaecology of Shree Krishna Hospital Pramukh Swami Medical College, Bhaikaka
75 university, Karamsad, Anand, Central Gujarat, India. This is a 750-bedded tertiary care
76 institute that caters to Anand and Kheda districts, over an area of about 50 km radius.

77

78 **2.4 Data Setting**

79 Data of the patients who had received MT was retrieved from our files and A.D. Gorawala
80 blood bank. The following details about the patient were collected. The patient's detailed
81 performa included patient ID number, age, profession, socioeconomic status, gravida, parity,
82 details of current pregnancy, mode and time of delivery, cause of obstetric haemorrhage,
83 coagulation profile, the timing of onset of haemorrhage to the onset of MT interval, number
84 of blood products transfused, its relative ratio of RBC:FFP:Platelets and cryoprecipitates,
85 hospital stay, ICU stay, the occurrence of complications like TRALI (transfusion-associated
86 acute lung injury), TACO (transfusion-associated circulatory overload), Acute Renal
87 Shutdown, Blood transfusion reaction, the need for mechanical ventilation, the need of
88 dialysis and vital organ failure and the final outcome as survival or mortality.

89

90 **2.5 Ethical Clearance**

91 The data collection was started after approval of the institutional ethics committee-
92 **IEC/BU/136/Faculty/1/293/2022**, as it was a prospective and descriptive study, a waiver of
93 consent was requested.

94

95 **2.6 Statistical analysis**

96 Descriptive and multivariate logistic regression were used to analyse data by using the
97 SPSS 29 software. Indescriptive statistics mean [SD] and frequency [%] were used to depict
98 the baseline profile of the study participants. A p value <0.05 was considered as statistically
99 significant.

100

101

102

103

104 **3. RESULTS**

105

106 The study was conducted between July 2022 to January 2024. There were total 2956
107 obstetric admissions out of which 81 patients required massive blood transfusion which
108 accounts for 2.74% of the MTP utilization rates. Highlighting the demographical data, the
109 minimum age of the patients requiring MTP was 19yrs and the maximum age was 38yrs.
110 The mean age of the study population was 27.3 years.

111 Table 1 shows that out of the total 81 cases, 68 cases i.e. 84 % cases belonged to rural
112 area. Maximum number of patients belonged to middle class socioeconomic status i.e. 51
113 cases out of the total 81 cases (63%). Amongst the study cases, antenatal patients were in
114 the majority with 47 (58%) of the total cases, while the rest were post-partum patients.
115 Majority of the patients were multipara-50 (61.7%) followed by primipara cases being 21
116 (26%). Parity of more than 4 were considered to be grand multipara. **Atonic postpartum
117 hemorrhage (PPH) was more common among multiparous women. The category of patients**

118 under 20 weeks included those with missed or incomplete abortions, ruptured ectopic
 119 pregnancies, abdominal pregnancies, and early-diagnosed placenta accreta syndrome.

120

121

TABLE 1: DEMOGRAPHIC VARIABLES

VARIABLES	NO. OF PATIENTS (n=81)	PERCENTAGE (%)
AGE		
15-20	6	7.4
21-25	22	27.2
26-30	33	40.7
31-35	14	17.3
36-40	6	7.4
LOCALITY		
Rural	68	84
Urban	13	16
SOCIOECONOMIC CLASS		
Upper middle class	7	8.6
Middle middle class	51	63
Lower class	23	28.4
PREGNANCY STATUS		
ANC	47	58
PNC	34	42
PARITY		
Nullipara	10	12.3
Primipara	21	26
Multipara	44	54.3
Grand multipara	6	7.4
GESTATIONAL AGE AT PRESENTATION		
<20	6	13.3
20-28	3	6.6
28-37	23	46.65
37-42	15	33.3

122 At Shree Krishna Hospital, the largest proportion of patients requiring Massive Transfusion
123 Protocol (MTP)—26 cases, or 32%—had undergone a lower segment cesarean section
124 (LSCS). Most of these cases were complicated by antepartum hemorrhage, including
125 placenta previa, placental abruption, and placenta accreta syndrome, necessitating either
126 emergency or elective LSCS.

127 Additionally, 9 patients (11.1%) in the laparotomy category underwent procedures such as
128 uterine rupture repair, hemoperitoneum drainage, stepwise devascularization, or obstetric
129 hysterectomy. These cases included uterine rupture, ruptured ectopic pregnancy, abdominal
130 pregnancy, placenta accreta spectrum, and traumatic PPH.

131 **TABLE 2 : CAUSES OF HEMORRHAGE**

CAUSES OF HEMORRHAGE	NO. OF CASES	PERCENTAGE
ATONIC/ TRAUMATIC PPH	29	37
ABRUPTIO PLACENTA	17	21
DIC/ HELLP/ THROMBOCYTOPENIA	17	21
PLACENTA ACCRETA SYNDROME	8	9.8
PLACENTA PREVIA	4	5
RUPTURED ECTOPIC	3	3.7
RUPTURED UTERUS	2	2.5
ABDOMINAL PREGNANCY	1	1.2
TOTAL	81	100

132

133 Table 2 shows that the most prevalent cause of massive obstetric hemorrhage was
134 postpartum hemorrhage (PPH), accounting for 37% of cases. This category includes those
135 cases specifically associated with atonic and/or traumatic PPH. Other contributors to PPH,
136 such as thrombin defects and retained placenta, are detailed in separate sections:
137 DIC/HELLP/thrombocytopenia (17 cases, 21%) and placenta accreta spectrum (PAS) (8
138 cases, 9.8%).

139 For cases of antepartum hemorrhage (APH), the most common cause was placental
140 abruption, occurring in 17 cases (21%), while placenta previa was observed in 4 cases (5%).
141 Abdominal pregnancy was the least common, with only 1 case out of the total 81 cases, and
142 ruptured ectopic pregnancy was noted in 3 cases.

143 Many patients presented with multiple overlapping comorbidities. A significant portion,
 144 66.6%, exhibited deranged coagulation profiles, which included conditions such as HELLP
 145 syndrome, DIC and thrombocytopenia. Among those with hypertensive disorders of
 146 pregnancy, preeclampsia was the most common condition necessitating massive
 147 transfusions, affecting 43.2% of the cases. Additionally, 31% of the patients had a history of
 148 previous lower segment cesarean sections (LSCS). Sepsis was observed in 24.7% of the
 149 patients upon admission, often associated with atonic, traumatic, or secondary postpartum
 150 hemorrhage (PPH), particularly in cases involving multiple per vaginal examinations. Four
 151 patients had pre-existing cardiac conditions, including rheumatic heart disease with post-
 152 valve replacement, ongoing anticoagulant therapy, as well as, peripartum cardiomyopathy
 153 (PPCM). Acute kidney injury (AKI) was present in 14.8% of patients on admission,
 154 characterized by elevated serum creatinine levels exceeding 1.5 mg/dL, primarily due to pre-
 155 renal factors like acute blood loss. Furthermore, 29.6% of patients were diagnosed with
 156 multiorgan dysfunction syndrome (MODS) upon admission, attributable to underlying
 157 conditions such as HELLP syndrome, preeclampsia, and eclampsia. This often involved the
 158 simultaneous impairment of multiple systems, including hematological, renal, liver function,
 159 cardiac, respiratory, and/or central nervous systems (CNS).

160 In this study, the majority of postpartum hemorrhage (PPH) cases were attributed to uterine
 161 atony - 50.6% . Traumatic PPH was observed in 12.3% . Additionally, 7.4% of cases
 162 involved both atonic and traumatic PPH. Coagulation disorders were present in 17.3% of the
 163 cases, encompassing issues such as clotting factor abnormalities and thrombocytopenia.
 164 Secondary PPH, occurring between 24 hours and 6 weeks postpartum, was identified in 5
 165 out of 81 cases. Other causes of PPH included ruptured ectopic pregnancies, placenta
 166 accreta spectrum (PAS), and abdominal pregnancies.

167 The shock index was the most frequently used parameter for assessing overall blood loss in
 168 patients. This index is calculated by dividing the pulse rate by the systolic blood pressure
 169 (SBP). In the majority of cases, 52% of patients had a shock index greater than 1. Those
 170 presenting with severe shock typically had experienced a loss of more than 30% of their total
 171 blood volume.

172 The average time from the collection of the blood sample to the issuance of the first blood
 173 product was 12 minutes, in this desperate requisition O Negative blood was issued.

174

175

176

177 **TABLE 3 :ON ADMISSION LABORATORY PARAMETERS, INTERVAL BETWEEN**
 178 **ONSET OF MOH TO MTP AND TOTAL BLOOD PRODUCTS GIVEN**

LAB PARAMETERS	RANGE	MEAN	MEDIAN
HEMOGLOBIN (GM/DL)	1.8-13.9	6.5	6.5
PLATLET (/MM³)	2000-3,98,000	139	136
PT	9.3-90	22.78	13.7

INR	0.79-9	1.93	1.17
APTT	14.1-135	41	28.8
FIBRINOGEN	30-580	212	188
CREATININE	0.24-4.7	0.98	0.71
K ⁺	3-6.8	4.15	4


INTERVAL BETWEEN ONSET OF MOH TO DECISION OF INITIATION OF MTP

TIME INTERVAL (HRS)	NO. OF PATIENTS	PERCENTAGE
0HRS	20	24.7
<2HRS	6	7.4
2-6HRS	41	50.6
6-12 HRS	10	12.3
>12 HRS	4	4.9

BLOOD PRODUCTS

	TOTAL	AVERAGE
PCV	388	4.8
FFP	402	5
PC	317	4
CP	736	9

180 Table 3 depicts the severity of anemia the patients presented with. The minimum was
 181 1.8gm/dl and the mean was 6.5gm/dl. One of the patients had a platelet count of 2000/mm³.
 182 Whereas one patient had a fibrinogen level of 30mg% on admission. This shows the
 183 extreme of the cases catered by the institute. All of the above-mentioned cases survived. In
 184 20 cases the onset of obstetric haemorrhage was within the hospital during vaginal delivery,
 185 LSCS or laparotomy so MTP could be initiated immediately. Such cases included both
 186 elective and emergency situations. However in maximum number of cases due to delayed



187 referral MTP could be initiated in 2-6 hrs(41 out of 81 cases).The total number of blood
 188 products given to 81 patients in the study were 1866, out of which 388 were PCV, 402 were
 189 FFP, 317 were PC and 736 were CP. The average number of PCVs, FFPs, PCs and CPs
 190 was thereby 4.8, 5, 4 and 9 respectively; this gave us a ratio of 1:1.02:0.8:2 of PCV:
 191 FFP: PC: CP transfusion, which means for every 50 units of PCV transfusion, 51 units of FFP,
 192 40 unit of PC and 100 units of CP was required.

193 **FIGURE 1 : SURGICAL INTERVENTIONS**

194 In the majority of cases, specifically 31 (38.2%), massive bleeding was successfully
 195 managed through the timely administration of oxytocics including oxytocin,
 196 methylergometrin, carboprost, carbetocin and misoprostol and the implementation of a
 197 massive blood transfusion protocol. This approach was crucial in preventing complications
 198 such as hypothermia, acidosis, and disseminated intravascular coagulation (DIC). As per
 199 Figure 1 when surgical interventions were necessary, obstetric hysterectomy was the most
 200 commonly performed procedure, with 16 total and 3 subtotal hysterectomies. Additionally,
 201 cervicovaginal exploration and intrauterine packing were used in 13.6% of the cases (11
 202 cases). Among the 81 cases reviewed, the SR cannula—a novel technique for managing
 203 atonic postpartum hemorrhage (PPH)—was employed in 5 cases (6.2%).

204 **TABLE 4: SPECIFIC COMPLICATIONS AFTER MASSIVE BLOOD TRANSFUSION**

205

COMPLICATIONS	NO. OF CASES	PERCENTAGE
TACO	13	16
TRALI	6	7.4
ELECTROLYTE IMBALANCE	2	2.4

206 Many of the complications are overlapping with patients showing more than 2 complications
207 at a time. Table 4 shows among those who developed complications, 13 patients (16%) had
208 transfusion-associated circulatory overload (TACO), and 6 patients (7.4%) had transfusion-
209 related acute lung injury (TRALI). Fluid management was closely monitored using the inferior
210 vena cava (IVC) status via bedside echocardiogram in the ICU. It is noteworthy that 46
211 patients (56.8%) had no complications.

212 Multiple organ dysfunction syndrome (MODS) was diagnosed in 41 patients likely due to the
213 severity of their preexisting conditions like preeclampsia, eclampsia, HELLP syndrome,
214 hepatic disorders of pregnancy and PPCM; they may act as a confounder so we cannot say
215 it was because of MT. Acute kidney injury (AKI) occurred in 6.2% of cases, primarily due to
216 acute blood loss and delayed referral; 33% of these AKI cases progressed to chronic renal
217 failure (CRF) requiring dialysis. Sepsis was observed in 7 patients (8.6%) by the end of the
218 massive transfusion (MT), resulting from either the progression of existing sepsis or
219 secondary infections related to prolonged hospital stays and invasive treatments like
220 ventilator-associated pneumonia (VAP). About 20% of the cases involved acute febrile
221 reactions, managed with antipyretics and antihistamines. The incidence of dilutional
222 coagulopathy decreased with the administration of blood products in a ratio of **1:1.02:0.8** for
223 packed cell volume (PCV), fresh frozen plasma (FFP), and platelet concentrates (PC). Most
224 post-MT complications were overlapping and related to the patients' underlying
225 comorbidities.

226 **TABLE 5 : CORRELATION OF THE BLOOD PRODUCTS TO COMPLICATIONS**

RELATION OF BLOOD PRODUCTS TO COMPLICATIONS ADJUSTED WITH HIGH-RISK MATERNAL FACTORS ON ADMISSION				
	p-value	OR with 95% CI	95% C.I. for OR	
			Lower	Upper
RCC	0.371	1.235	0.777	1.962
FFP	0.772	1.030	0.829	1.287
PC	0.097	1.264	0.967	1.498
CP	0.539	1.033	0.936	1.134
DIRECT RELATION OF SPECIFIC BLOOD PRODUCT TO TRALI (TRANSFUSION-RELATED ACUTE LUNG INJURY) AND TACO (TRANSFUSION ASSOCIATED CIRCULATORY OVERLOAD)				
RCC	0.771	1.105	0.565	2.160

FFP	0.170	1.303	0.893	1.901
PC	0.080	1.351	0.964	1.892
CP	0.652	1.047	0.857	1.279

227

228 Table 5 shows the relation to the chances of development of transfusion-related
 229 complications after specific blood product transfusion which was adjusted to on-admission
 230 maternal high-risk factors like hypertensive disorders of pregnancy, sepsis, placenta accreta
 231 spectrum, previous caesarean status, abruption and HELLP syndrome. The maximum
 232 chances of blood complications occur due to PC transfusion. It also depicts that the
 233 maximum chances of TRALI and TACO are with PC.

234 The average number of days for total hospital stay that the patients requiring massive blood
 235 transfusion was 8.9 days. In 95% of the cases patients required intensive care monitoring as
 236 well in ICU. Average days for ICU admission were 3.6 days. Many of the patients required
 237 mechanical ventilation. Average number of days required for mechanical ventilation was on
 238 an average 1.9 days.

239 Out of the 81 cases, 95% were successfully treated due to the timely administration of
 240 oxytocics, higher antibiotics, and the effective support of a well-equipped blood bank and
 241 laboratory. This was possible due to multidisciplinary approach and efficient work of
 242 obstetricians, anesthesia, intensive care team and blood bank. While maintaining proper
 243 aseptic precautions thus minimizing hospital acquired infections. In 4 (5%) cases, patients
 244 succumbed to irreversible shock and could not be salvaged. In 60% of the cases baby could
 245 be saved due to prompt decision of LSCS. While 31% of the cases were IUFD more
 246 commonly due to APH – abruption more than placenta previa. 9% of the abortal cases
 247 include ectopic pregnancy, abdominal pregnancy and incomplete/ missed abortion with PAS.

248 **TABLE 6 : COMPARISON OF RATIOS BETWEEN DIFFERENT STUDIES**

STUDIES	YEAR	CASES	PROTOCOL
Bonnet MP et al. ⁸	2011	38	FFP/RBC ratio exceeds 1 at 12 h following the onset of obstetric haemorrhage.
Matsunaga S et al. ⁹	2012	196	The medically necessary FFP/RCC ratio is 1.3 in obstetric haemorrhage.
Gutierrez MC et al. ¹⁰	2012	26	MTP was defined as a combination of 6 units of O-negative RBC, 4 units of FFP (liquid AB plasma or thawed type-specific plasma), and 1 apheresis platelet (PLT) unit.
Green L et al. ¹¹	2016	181	FFP/RBC ratio ≥ 1 is required during massive obstetrics haemorrhage.
Tanaka H et al. ¹²	2016	52	Transfusion of FFP/RBC ratio ≥ 1 reduces mortality

249

250 Table 6 compares the ratio of fresh frozen plasma (FFP) to red blood cells (RBC) across
 251 various studies. In present study, the ratio of FFP to packed cell volume (PCV), platelet
 252 concentrates (PC), and cryoprecipitate (CP) was 1.02:1:0.8:2. Several retrospective studies

253 have indicated that a higher plasma-to-RBC ratio in massive transfusion (MT) is linked to
254 improved survival rates in patients with traumatic injuries. Since 2007, there has been a
255 growing adoption of higher plasma-to-platelet-to-RBC ratios in MT therapy.

256

257 **4.DISCUSSION**

258 Trauma and obstetric patients have markedly different physiological profiles, which affect
259 hemorrhage management strategies. During pregnancy, physiological changes such as
260 hemodilution and increased cardiac output can mask significant bleeding, delaying detection
261 until hemoglobin and hematocrit levels drop significantly. Additionally, pregnancy-related
262 comorbidities can elevate the risk of severe bleeding, consumption coagulopathy, and the
263 early onset of organ failure and multiple organ dysfunction syndrome (MODS). These factors
264 necessitate distinct approaches to managing hemorrhage in obstetric cases compared to
265 trauma patients.

266 According to the RCOG's "Green-top Guideline: Blood Transfusion in Obstetrics" (October
267 2006), the recommended dosage for fresh frozen plasma (FFP) is 12-15 ml/kg for every 6
268 units of red blood cells (RBC). The guideline emphasizes using prothrombin time (PT) and
269 activated partial thromboplastin time (APTT) from coagulation tests as the primary indicators
270 for determining FFP requirements, with target levels set at 1.5 times the normal range for PT
271 and APTT, and a fibrinogen level of 150 mg/dl or higher. It also advises regular monitoring of
272 these tests and blood counts in cases of prolonged bleeding. Additionally, the guideline
273 recommends administering cryoprecipitate in two sets of five units to maintain fibrinogen
274 levels at or above 150 mg/dl.

275 The ACOG (May 2015) guidelines recommend an early and aggressive transfusion strategy
276 with a 1:1:1 ratio of red blood cells (RBC), fresh frozen plasma (FFP), and platelets (PC)
277 during massive transfusions. This approach aims to address coagulopathy, hypothermia,
278 and acidosis, which are critical factors that significantly increase the risk of patient
279 mortality¹³.

280 Poor outcomes following massive obstetric hemorrhage (MOH) and massive transfusion
281 (MT) are often due to delayed treatment, unavailability of blood products, inaccurate blood
282 loss estimation, lack of treatment protocols, and poor communication among team members.
283 In contrast, our study highlights that present institute has a benefit of a well-organized
284 multidisciplinary approach. This includes an equipped trauma care center, dedicated
285 obstetric team, efficient laboratory and blood bank services, anesthesia, operating theaters,
286 and a critical care team with ICU centers and dialysis units, all operating 24/7.

287 In the current study, 81 out of 2,956 obstetric admissions required massive blood transfusion
288 (MT), resulting in a utilization rate of 2.74%. This is higher than the 0.7% reported by Ochiai
289 D et al. in Japan¹⁴ but lower than the 3% observed by Paul I. Ramler et al. in the
290 Netherlands¹⁵. Notably, a 2020 study by S. Anuraga et al. in Puducherry¹⁶, India, reported a
291 much higher MT rate of 20%. The previous study at the same institute by Rumi
292 Bhattacharjee et al¹⁷ in 2017 had an MT rate of 2.4%. Regarding case distribution, the prior
293 study showed 60.9% antenatal and 39.1% postnatal cases, while the current study reports
294 58% antenatal and 42% postnatal cases. This slight shift, along with varying MT rates,
295 suggests evolving practices or patient profiles in obstetric care.

296 In the current study, the mean age of patients requiring massive blood transfusion (MT) was
297 27.3 years, with a range of 19 to 38 years. This is consistent with the mean age reported in
298 Puducherry, India, but lower than the 36.8 years observed in Japan and the 32 years in the
299 Netherlands. The previous study at the same institute noted that most patients were in the

300 21-30 years age group. These findings suggest that younger women are more commonly
301 affected in Asian countries, potentially due to earlier marriages and childbearing compared
302 to developed countries. Supporting this, Patricia et al. found that females under 20 years are
303 more susceptible to pregnancy complications, such as poor fetal growth and postpartum
304 hemorrhage (PPH). Additionally, a study on elderly primigravidas indicated that 3%
305 experienced antepartum hemorrhage and 3% had PPH, further highlighting the impact of
306 age on pregnancy outcomes.

307 As per the Quality Improvement Program survey conducted in American College of
308 surgeons, 2013 during the pre-hospital resuscitation the most common blood products used
309 were RBCs and plasma, while the most common intravenous hemostatic agent is
310 Tranexamic Acid. Hypotension with SBP \leq 100mmhg was the most common MTP trigger.
311 Laboratory values were infrequently used to initiate MT. Amongst the blood products plasma
312 is immediately available in <5 minutes. most common plasma type used is thawed plasma.
313 The most common FFP:RBC ratio in the first cooler is \geq 1. Use of cryoprecipitates is also
314 encouraged in MT. In the present institute the shock status of the patients was assessed by
315 shock index of the patient (Pulse/ SBP), urine output and by calculating the average amount
316 of blood loss of the patient. In the present institute the average time interval between the
317 blood collection and issuing of the first blood product is 12 min. The most common
318 hemostatic agent used is injectable TRANEXAMIC ACID followed by injectable
319 HEMOCOAGULASE (BOTROPACE). The facility of TEG (thromboelastography) is not
320 currently available in present institute.

321 Le Bas et al.¹⁸ recently highlighted that during pregnancy, the normal shock index (pulse rate
322 divided by systolic blood pressure) is typically higher compared to non-pregnant adults. This
323 increase is due to a higher pulse rate and a decrease in systolic blood pressure. An obstetric
324 shock index (OSI) greater than 1 is associated with a higher likelihood of requiring a blood
325 transfusion following postpartum hemorrhage (PPH). Consequently, the OSI can serve as a
326 useful bedside clinical tool for assessing the degree of blood loss, offering a more reliable
327 measure than visual estimation, which is prone to significant observer variability. The latest
328 Green Top Guideline from the Royal College of Obstetricians and Gynaecologists
329 underscores the importance of the OSI in identifying women at risk of adverse outcomes. In
330 the present study, 26% of patients were categorized with moderate shock (SI between 1 and
331 1.39), while another 26% were in severe shock (SI \geq 1.4). On average, patients with severe
332 shock experienced blood loss exceeding 30% of their total blood volume. As compared to
333 Rumi et al which was a retrospective study, blood products transfusion was decided by
334 physician whereas in the current study which is a prospective study the determinants for
335 blood transfusion were the clinical status of the patient and lab parameters including the
336 Shock Index(SI), coagulation profile and obstetric parameters.

337 As per literature, the proportion of patients with previous caesarean sections varies, with
338 Ramer et al. reporting 23%, S. Anuraga et al. indicating 33.3%, and the current study
339 showing a rate of 31%. A history of caesarean sections, along with prior myomectomy or
340 dilatation and evacuation, is linked to increased risks in subsequent pregnancies. These
341 risks include uterine rupture, dense adhesions, placenta previa, and placenta accreta
342 syndrome. Notably, the risk of placenta accreta syndrome rises with the number of previous
343 caesarean sections, thereby increasing the likelihood that a patient may require an obstetric
344 hysterectomy in future pregnancies.

345 Among the causes of obstetric hemorrhage, the single most common cause is post-partum
346 hemorrhage – which includes all the 4Ts -tone, thrombin, tissue and trauma. In the present
347 study (year 2022 to 2024) atonic PPH accounts for 50.6% of the cases while it was 33.5% in

348 previous study of the same institute (year 2014 to 2017 published in 2019). It was 58.3 % in
349 the study conducted in Japan and 57% in Netherlands study.

350 In the present study, peripartum hysterectomy was necessary in 23.4% of cases involving
351 obstetric hemorrhage. The primary causes for this intervention were atonic postpartum
352 hemorrhage (PPH), traumatic PPH, followed by placenta accreta syndrome and uterine
353 rupture. This rate is comparable to the 23% reported by Rumi Bhattacharjee et al. (2017) but
354 higher than the 11% observed in a study conducted in Puducherry. In contrast, rates in
355 developed countries vary significantly, with Ochiai D et al. reporting 4.2% and Paul I. Ramler
356 et al. reporting 30%. Peripartum hysterectomy is generally considered a last-resort surgical
357 intervention, employed when patients do not respond to aggressive medical management
358 and conservative organ-preserving techniques.

359 Mortality rates following peripartum hysterectomy differ markedly between developed and
360 developing countries. In developed nations, such as the Netherlands, mortality is low at
361 1.08%. However, in developing countries, rates are significantly higher, with 11.1% in
362 Puducherry, 10% in a previous study from the current institute, and 5% in the present study.
363 Common causes of mortality include MODS, ARDS, sepsis, and acute kidney failure.
364 Research suggests that early activation of massive transfusion protocols (MTP) and
365 improved antenatal care to identify high-risk patients can help prevent severe outcomes and
366 reduce mortality

367 In the current study, among 81 cases, 46 (56.8%) did not experience complications related
368 to massive blood transfusion. This favorable outcome is attributed to effective fluid
369 management, monitored through the patient's IVC status using a bedside ECHO machine in
370 the ICU. Among the complications, Multiple Organ Dysfunction Syndrome (MODS) was the
371 most common, likely due to the underlying pathophysiology of the patients. Transfusion-
372 related acute lung injury (TRALI) was observed in 7.4% of cases, while transfusion-
373 associated circulatory overload (TACO) occurred in 16%.

374 The risk of TRALI varies by blood product, with one case per 5,000 PRBCs, one per 2,000
375 FFP, and one per 400 platelets¹⁹⁻²¹. A recent ICU study found an 8% incidence of TRALI,
376 with platelet or FFP transfusions increasing the risk nearly threefold. In present study, the
377 odds ratios for developing TRALI were 1.351 for platelet transfusions, 1.303 for FFP, 1.105
378 for PRBCs, and 1.047 for cryoprecipitate. Dilutional coagulopathy was observed in only 16%
379 of cases, as the PCV:FFP ratio is maintained at 1:1:1. Fibrinogen replacement, through
380 cryoprecipitate or fibrinogen concentrate, has proven effective in managing obstetric
381 hemorrhage and other conditions, with several studies supporting its efficacy. As per a study
382 conducted in Department of Obstetrics and Gynecology, Baylor College of Medicine,
383 Houston, Texas between 2014-2020 uterine atony was found to be the commonest etiology
384 for massive hemorrhage (34%), followed by placenta accreta spectrum (32%). A mean of 6.5
385 units of packed red blood cells, 14.8 units of fresh frozen plasma and cryoprecipitate, and
386 8.3 units of platelets were transfused per patient²².

387 **5.CONCLUSION –**

388 In the present study, the utilization rate of the massive transfusion protocol (MTP) was
389 2.74%. Postpartum hemorrhage (PPH) emerged as the primary cause of obstetric
390 hemorrhage. To enhance maternal morbidity and mortality outcomes, early referral to tertiary
391 care centers, timely administration of oxytocics, and the prompt initiation of MTP and
392 surgical interventions are crucial in managing cases of uncontrolled bleeding.

393 Maintaining a blood product ratio of 1:1.02:0.8 for PCV:FFP:Platelets proved effective in
394 preventing coagulopathy, ensuring adequate tissue perfusion, and protecting patients from
395 the detrimental cycle of sepsis, hypothermia, hemodilution, and shock. MT related
396 complications were managed by assessing fluid status through chest auscultation and
397 bedside ECHO for IVC status in the ICU, which provided valuable guidance in managing
398 these complications.

399 Additionally, slightly increasing the proportion of FFP transfusion relative to PCV, as
400 determined by interval blood testing, can support early hemostasis. This approach helps in
401 optimizing the balance of blood products and improving overall patient outcomes during
402 massive transfusions. All the facilities serving obstetric patients must have an established
403 protocol so that prompt treatment of obstetric patients can improve their survival.
404

405 **ACKNOWLEDGEMENTS**

406
407 We express our sincere thanks to the Dean of Pramukhswami Medical
408 College,Supreintendent of Shree Krishna Hospital, Karamsad and Provost of Bhaikaka
409 University, Karamsad for pratonage, permission and provision of all infrastructure facilities to
410 undertake this study and for letting me use patient details.

411 **COMPETING INTERESTS**

412
413 Authors have declared that no competing interest exist.
414

415 **AUTHORS' CONTRIBUTIONS**

- 416
- 417 • Dr. SmrutiBVaishnavhas helped in conceiving the idea, analysis, manuscript;
 - 418 • Dr. Rashmita Pal has written the project, done the data collection, analysis and has
419 written the manuscript.
 - 420 • Dr. Sangita Pandey has also contributed in writing the project, in analysis, and
421 writing the manuscript.
 - 422 • Mr. Mayur Shinde has helped with the statistical data analysis.
 - 423 • Dr. Akshay Padaliya has contributed in data collection and writing the manuscript.
424
425

426 **CONSENT**

427
428 Thiswasanobservationalstudy. Dataofthepatientswerecollectedfromthefileofthepatients.
429
430

431 **ETHICAL APPROVAL**

432
433 The data collection was started after approval of the institutional ethics committee-
434 **IEC/BU/136/Faculty/1/293/2022**, as it was a prospective and descriptive study, a waiver of
435 consent was requested.
436

437 ***Authors contributions***

438 ^a*Conceiving the idea, analysis, manuscript*

439 ^b*Writing the project, data collection, analysis, manuscript*

440 ^c*writing the project, analysis, manuscript*

441 ^d*statistical data analysis*

442 ^e*data collection, manuscript*

443

444

445 **DISCLAIMER**

446

447 Author(s) hereby declare that NO generative AI technologies such as Large Language
448 Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during
449 writing or editing of manuscripts.

450

451 **REFERENCES**

452 1. Fabry SM Sheldon GF, et al. Massive transfusion in the surgical patient; American
453 association of blood bank 1994; 135-156.

454 2. Balasudha K panikar S massive obstetric haemorrhage; Our experiences,
455 International Journal of Reproduction, Contraception, Obstetric and gynaecology
456 2014 March; 3(1).

457 3. Gungar T Smisek A et al. Surgical treatment of interactable postpartum
458 haemorrhage and changing trends in medium Obstetric perspective. Arch
459 Gynaecology obstetric 2009; 280; 351-355 DOI:10:1007 / s00404-008-0914%.

460 4. Ickx BE, Fluid and blood transfusion management in obstetrics. Eu Anaesthesiology
461 2010;27:1031-5.

462 5. Brohik, Cohen M J Devenport RA Acute coagulopathy of trauma: mechanism,
463 identification and effect. Curr opinion critical care; 13:680-5.

464 6. Lloyed Ketcham, John R Hess Seppo Hippalenindicacious for early fresh frozen
465 plasma, cryoprecipitates nd Platelet transfusion in trauma; The journal of
466 trauma.01/7 /2006; 60 (6 suppl):551-8.

467 7. Hiroaki Tanaka, ShigetakaMatsunga, Tomoyuki Yamashita et al. A systemic review
468 of MTP in obstetrics. Taiwanese Journal of obstetrics and gynaecology. Sb
469 (2017)715-718.

470 8. M.P. Bonnet, C. Deneux-Tharaux, M.H. Bouvier-Colle Critical care and transfusion
471 management in maternal deaths from postpartum haemorrhage,
472 EurJObstetGynecolReprodBiol, 158 (2011), pp. 183-188

473 9. S. Matsunaga, H. Seki, Y. Ono, H. Matsumura, Y. Murayama, Y. Takai, *et al.*,
474 A retrospective analysis of transfusion management for obstetric hemorrhage in a
475 Japanese obstetric center, ISRN ObstetGynecol, 2012 (2012), p. 854064

476 10. M.C. Gutierrez, L.T. Goodnough, M. Druzin, A.J. Butwick, Postpartum hemorrhage
477 treated with a massive transfusion protocol at a tertiary obstetric center: a
478 retrospective study, Int J ObstetAnesth, 21 (2012), pp. 230-235

479 11. L. Green, M. Knight, F. Seeney, C. Hopkinson, P.W. Collins, R.E. Collis, *et al.*, The
480 haematological features and transfusion management of women who required
481 massive transfusion for major obstetric haemorrhage in the UK: a population based
482 study, Br J Haematol, 172 (2016), pp. 616-624

- 483 12. H. Tanaka, S. Katsuragi, T. Ikeda, K. Osato, J. Hasegawa, M. Nakata, *et al.*,
484 Efficacy of transfusion with fresh-frozen plasma:red blood cell concentrate ratio of 1
485 or more for amniotic fluid embolism with coagulopathy: a case-control study,
486 *Transfusion*, 56 (2016), pp. 3042-3046
- 487 13. Cotton BA, Guy JS, Morris Jr JA, Abumrad NN. The cellular, metabolic, and
488 systemic consequences of aggressive fluid resuscitation strategies. *Shock*
489 2006;26:115e21.
- 490 14. Ochiai, D.; Abe, Y.; Yamazaki, R.; Uemura, T.; Toriumi, A.; Matsushashi, H.; Tanaka,
491 Y.; Ikenoue, S.; Kasuga, Y.; Tanosaki, R.; et al. Clinical Results of a Massive Blood
492 Transfusion Protocol for Postpartum Hemorrhage in a University Hospital in Japan:
493 A Retrospective Study. *Medicina* 2021, 57, 983. [https://doi.org/10.3390/](https://doi.org/10.3390/medicina57090983)
494 [medicina57090983](https://doi.org/10.3390/medicina57090983)
- 495 15. Ramler PI, van den Akker T, Henriquez DDCA, et al. Women receiving massive
496 transfusion due to postpartum hemorrhage: A comparison over time between two
497 nationwide cohort studies. *Acta ObstetGynecol Scand.* 2019;98(6):795-804.
498 doi:10.1111/aogs.13542
- 499 16. Anuragaa S, Chaturvedula L, Basavarajegowda A. Blood component therapy in
500 patients having massive obstetric hemorrhage in a tertiary care center in
501 Puducherry. *Asian J Transfus Sci* 2023;17:210-6.
- 502 17. Bhattacharjee R, Raithatha N, Sapre S. An Analysis of Large Volume Blood and
503 Blood Product Transfusion in Critically Ill Obstetric Patients: A Retrospective Study.
504 *J South Asian Feder Obst Gynae* 2019;11(3):148–152
- 505 18. Le Bas A, Chandraharan E, Addei A, et al. Use of the “obstetric shock index” as an
506 adjunct in identifying significant blood loss in patients with massive postpartum
507 hemorrhage. *Int J GynecolObstet* 2013;124(3):253–255. DOI:
508 10.1016/j.ijgo.2013.08.020.
- 509 19. GazmuriRJ, Shakeri SA . Blood transfusion and the risk of nosocomial infection: an
510 underreported complication? *Crit Care Med* .2002 ; 30 (10): 2389 - 2391 .
- 511 20. Silliman CC , Paterson AJ , Dickey WO , et al . The association of biologically active
512 lipids with the development of transfusion-related acute lung injury: a retrospective
513 study .*Transfusion* .1997 ; 37 (7): 719 - 726 .
- 514 21. Wallis JP ,Lubenko A , Wells AW , Chapman CE . Single hospital experience of
515 TRALI .*Transfusion* .2003 ; 43 (8): 1053 1059 .
- 516 22. Salmanian B, Clark SL, Hui SR, et al. Massive Transfusion Protocols in Obstetric
517 Hemorrhage: Theory versus Reality. *Am J Perinatol.* 2023;40(1):95-98.
518 doi:10.1055/s-0041-1728833
- 519

520
521

ABBREVIATION

AKI	Acute Kidney Injury
ANC	Antenatal Care
APH	Antepartum Hemorrhage
APTT	Activated Partial Thromboplastin Time
ART	Artificial Reproductive Techniques
ATLS	Advanced Trauma Life Support
CP	Cryoprecipitate
DIC	Disseminated Intravascular Coagulation
FFP	Fresh Frozen Plasma
Hb	Hemoglobin
HDU	High Dependency Units
INR	International Normalized Ratio
IVC	Inferior Vena Cava
LSCS	Lower Segment Cesarean Section
MODS	Multiorgan Dysfunction Syndrome
MOH	Massive Obstetric Hemorrhage
MT	Massive Transfusion
MTP	Massive Transfusion Protocol
OSI	Obstetrics Shock Index
PC	Platelet Concentrate
PCV	Packed Cell Volume
PLT	Platelet
PNC	Postnatal Care
PPH	Postpartum Hemorrhage
PPROM	Preterm Premature Rupture Of Membranes
PROM	Premature Rupture Of Membranes
PT	Prothrombin Time
RBC	Red Blood Concentrates
RCC	Red Cell Concentrate

SI	Shock Index
SR canula	Samarth Ram suction canula
TEG	Thromboelastography
WHO	World Health Organization